Glaucoma 360 New Horizons Forum
Glaucoma 360 New Horizons Forum
February 10, 2020
1 min read

iDose lowers IOP, shows no significant adverse events in phase 2 trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Jane Rady

SAN FRANCISCO — The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker here.

Designed to be an alternative to topical medications for the treatment of glaucoma, the iDose delivers a novel, uber-potent formulation of travoprost through an implant injected directly into the sclera via a preloaded injector system.

“In using the microfluidic delivery systems that we designed for the MIGS space, we have modified those to get into long-term drug delivery,” Jane Rady, Glaukos senior vice president, said at Glaucoma 360: New Horizons Forum.

A phase 2 study compared two elution rates of the iDose with topical timolol. Both iDose travoprost cohorts showed IOP reduction between 8 mm Hg and 8.5 mm Hg compared with an average reduction of 7.5 mm Hg in the timolol cohort.

“Both of the iDose cohorts had less medications required post-surgery than the timolol, 31% less, and there were no significant adverse events, no hyperemia in these patients,” Rady said. “The membrane is uniquely designed and the formulation such we can deliver a therapeutic dose of travoprost and eliminate the side effects associated with topical applications.”

A three-arm, sham-controlled phase 3 clinical trial of iDose is currently underway. Patients will be monitored for noninferiority to timolol at 3 months and safety at 12 months.

“We are very optimistic that they’re going to provide a duration that’s going to make this a clinically appropriate treatment for these patients,” Rady said. – by Rebecca L. Forand



Rady J. A novel, long-term, sustainable drug delivery platform. Presented at: Glaucoma 360: New Horizons Forum; Feb. 7, 2020; San Francisco.


Disclosure: Rady reports she is senior vice president of Glaukos.